NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Launched by BAYER · Jun 29, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called larotrectinib for patients with a rare type of cancer known as TRK fusion cancer. This cancer happens when a gene called NTRK fuses with another gene, leading to the growth of cancer cells. Larotrectinib is designed to block the effects of this gene fusion, helping to stop the cancer from spreading. The researchers want to gather more information about how safe and effective this treatment is for both adults and children with advanced or recurrent TRK fusion cancer, meaning their cancer has either spread to other parts of the body or has come back after treatment.

To participate in the trial, patients must be currently receiving larotrectinib as part of their regular care. There are no extra tests or visits required for this study; instead, researchers will collect information from patients’ medical records and have interviews with them or their guardians during regular doctor visits. They plan to track the health of adult participants for about two years and children for up to eight years, noting any medical problems that may arise. This study aims to provide important insights to help improve treatment options for patients with TRK fusion cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are treated with larotrectinib or decided to be treated with larotrectinib, under routine clinical practice.
• Exclusion Criteria:
• • Participation in an investigational program with interventions outside of routine clinical practice